Home
½ÃÀÛÆäÀÌÁö
Áö³È£º¸±â
·Î±×ÀÎ
ȸ¿ø°¡ÀÔ
±¸µ¶½Åû
Àüü±â»ç
2024-03-29 ±Ý 00:39
±â»ç°Ë»ö
Cover Story
¼øȯ±â
³»ºÐºñ
È£Èí±â
¼Òȱâ
½Å°æ°ú
Á¤½Å°Ç°
°¨¿°³»°ú
Sub Story
Interview
Drug Review
Conference Report
Late Breaking Studies
Expert Opinion
Primary Expert Opinion
The Rare Disease
ÇмúÀÚ¹®À§¿ø
RTM
»ó´Ü¿©¹é
񃯇
(Àüü 772°Ç)
Á¦¸ñº¸±â
Á¦¸ñº¸±â
Á¦¸ñ+³»¿ë
[Sub Story]
3Á¦¿ä¹ý, ¸®¾ó¿ùµå ÁßÁõ ¾ÇÈ È¯ÀÚ¿¡¼ ÀÏ°üµÈ ÇýÅÃ
ÀÓ¼¼Çü ±âÀÚ
2022-04-11 14:29
[Sub Story]
LAMA ÃÊÄ¡·á, 3Á¦¿ä¹ý À§Çè°¨¼Ò
ÀÓ¼¼Çü ±âÀÚ
2022-04-11 14:24
[Sub Story]
ÇǸ£Æä´Ïµ·, Ãʱâ»ç¿ë ±Ù°Å È®º¸µÆ´Ù
ÀÓ¼¼Çü ±âÀÚ
2022-04-11 13:48
[Deep in Guideline]
COVID-19 »óȲº° ¾à¹°¿ä¹ý Àû¿ë¹æÇâ Á¦½Ã
ÀÓ¼¼Çü ±âÀÚ
2022-04-11 13:42
[Conference Report]
Å×Á¦Æç·ç¸¿, ÁßÁõ õ½Ä Ä¡·áÈ¿°ú ±Ù°Å È®º¸
ÀÓ¼¼Çü ±âÀÚ
2022-04-11 12:10
¶óÀÎ
[Conference Report]
º¥¶ö¸®ÁÖ¸¿, ¸®¾ó¿ùµå ¿¬±¸¼ È¿°ú ÀÔÁõ
ÀÓ¼¼Çü ±âÀÚ
2022-04-11 11:57
[Conference Report]
´ëÇѼÒȱâ±â´É¼ºÁúȯ¡¤¿îµ¿ÇÐȸ 'APNM 2022' °³ÃÖ
ÀÓ¼¼Çü ±âÀÚ
2022-03-10 14:30
[Sub Story]
ÀÓ»óÇöÀå¿¡¼ °¡Á¤Ç÷¾Ð Àû±Ø Àû¿ë ÇÊ¿äÇÏ´Ù
ÀÓ¼¼Çü ±âÀÚ
2022-03-08 17:50
[Deep in Guideline]
CKD ȯÀÚ¿¡¼µµ Áø·á½Ç ¿Ü Ç÷¾Ð Á߿伺 °Á¶
ÀÓ¼¼Çü ±âÀÚ
2022-03-08 17:40
[Sub Story]
9¸í Áß 1¸í CKD ȯÀÚ
ÀÓ¼¼Çü ±âÀÚ
2022-03-08 17:21
¶óÀÎ
[Sub Story]
RAS¾ïÁ¦Á¦ 1Â÷Ä¡·á ±Ç°í
ÀÓ¼¼Çü ±âÀÚ
2022-03-08 17:06
[Conference Report]
½Ç·Î½ºÅ¸Á¹ DAPT ¡®¸ÂÃãÄ¡·á¡¯ Àü·«¿¡ ÇÑ ¹ß ´õ
ÀÓ¼¼Çü ±âÀÚ
2022-03-08 16:32
[Conference Report]
NOAC ÇãÇ÷¼º ³úÁ¹Áß ¿µ¿ª¿¡ ÀÚ¸®Àâ´Ù
ÀÓ¼¼Çü ±âÀÚ
2022-03-08 15:44
[Sub Story]
CGM »ç¿ëÀÔÁö È®Àå Áß
ÀÓ¼¼Çü ±âÀÚ
2022-02-07 17:16
[Interview]
¡°CGM, A1C º¸¿Ï Àü·«À¸·Î ÀÚ¸®Àâ¾Ò´Ù¡±
ÀÓ¼¼Çü ±âÀÚ
2022-02-07 17:10
¶óÀÎ
[Sub Story]
¡®CVD Ä¡·áÀü·«¡¯ SGLT-2i ÀÔÁö È®ÀÎ
ÀÓ¼¼Çü ±âÀÚ
2022-02-07 16:38
[Sub Story]
2022 ADA, ¸¸¼º½ÅÀåÁúȯ º°µµ éÅÍ °Á¶
ÀÓ¼¼Çü ±âÀÚ
2022-02-07 15:17
[Sub Story]
Àü¹ÝÀûÀÎ °¨¼ÒÃß¼¼ ¼Ó °í·É¿¡¼´Â ³ôÀº ºñÀ²
ÀÓ¼¼Çü ±âÀÚ
2022-02-07 15:10
[Sub Story]
ÃÖÀûÀÇ Ä¡·á´Â Á¤È®ÇÑ Áø´ÜºÎÅÍ
ÀÓ¼¼Çü ±âÀÚ
2022-01-04 14:30
[Sub Story]
HBVr °£ºÎÀü ȯÀÚ¿¡¼ ¼±Á¦Àû NUC Àü·« °í·Á
ÀÓ¼¼Çü ±âÀÚ
2022-01-04 14:30
-
1
2
3
4
5
6
7
8
9
10
´ÙÀ½
-
¿©¹é
Sub
news
¡°ACEI ÀÓ»ó±Ù°Å ³õ°í, ȯÀÚ ¼³µæÇÏÀÚ¡±
Q. Ç÷¾Ð°ÇÏ Ãø¸é¿¡¼ ACEIÀÇ Æ¯¼ºÀº?ù...
¡°SGLT-2i Ȳ±Ý±â´Â TZD¿Í º´¿ëÀ¸·ÎºÎÅÍ¡±
Q. SGLT-2iÀÇ °è¿È¿°ú¿¡ ´ëÇÑ °ßÇØ´Â...
¡°°í°µµ ½ºÅ¸Æ¾ Á¦Á¦ È¿°ú ´ëµîÇϳª ¾ÈÀü¼º ´Ù¸¦ ¼öµµ¡±
Q. CAD ȯÀÚÀÇ ÀÌ»óÁöÁúÇ÷Áõ Ä¡·áÀü·«Àº?...
¿©¹é
¿©¹é
Back to Top